

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOCON BIOLOGICS INC.,
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

IPR2024-00298
Patent 11,253,572 B2

Petitioner's Amended Mandatory Notices

Biocon Biologics Inc. (“Petitioner”) submits the following amended mandatory notices to identify additional related matters and to update back-up counsel information.

A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)).

Petitioner Biocon Biologics Inc., Biocon Limited, Biocon Biologics Limited, Biocon Biologics UK Limited, and Biosimilar Collaborations Ireland Limited are real parties-in-interest (“RPIs”) to the current Petition. Biocon Biologics Limited is a subsidiary of Biocon Limited, a publicly traded company. Biocon Biologics UK Limited is a wholly owned subsidiary of Biocon Biologics Limited, and Biosimilar Collaborations Ireland Limited and Biocon Biologics Inc. are wholly owned subsidiaries of Biocon Biologics UK Limited.

Further RPIs include Mylan Pharmaceuticals Inc. (“Mylan”) and Johnson & Johnson. Viatris Inc. and Mylan Inc. are parent companies of Mylan Pharmaceuticals Inc. Accordingly, Viatris Inc., Mylan Inc., and Mylan Pharmaceuticals Inc. are identified as RPIs to the current Petition. Momena Pharmaceuticals, Inc. and Janssen Research & Development LLC are wholly-owned subsidiaries of Johnson & Johnson, a publicly held company. Momena Pharmaceuticals, Inc., Janssen Research & Development LLC, and Johnson & Johnson are also RPIs to the current Petition.

No other parties exercised or could have exercised control over this Petition;

no other parties funded, directed, and controlled this Petition. *See* Trial Practice Guide, 15-16 (November 2019).

B. RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) (AMENDED).

Petitioner identifies *Samsung Bioepis Co., Ltd. v. Regeneron Pharms., Inc.*, IPR2023-00884 (P.T.A.B.), *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2022-01225 (P.T.A.B.), and *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2022-01226 (P.T.A.B.). Petitioner also identifies *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2021-00880 (P.T.A.B.), *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2021-00881 (P.T.A.B.), *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2023-00099 (P.T.A.B.), *Biocon Biologics Inc. v. Regeneron Pharms., Inc.*, No. IPR2024-00201 (P.T.A.B.), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 2023-1395 (Fed. Cir.), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 2023-1396 (Fed. Cir.), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, 1:22-cv-00061-TSK (N.D.W. Va.); *Regeneron Pharms., Inc. v. Celltrion, Inc.*, 1:23-cv-00089-TSK (N.D.W. Va.); *Regeneron Pharms., Inc. v. Samsung Bioepis Co. Ltd.*, 1:23-cv-00094-TSK (N.D.W. Va.); *Regeneron Pharms., Inc. v. Formycon AG*, 1:23-cv-00097-TSK (N.D.W. Va.); *Regeneron Pharms., Inc. v. Samsung Bioepis Co. Ltd.*, 1:23-cv-00106-TSK (N.D.W. Va.); and *Regeneron Pharms., Inc. v. Amgen Inc.*, 2:24-cv-00264-JAK-E (C.D. Cal.). To the best of Petitioner's knowledge, the following are additional judicial or administrative matters that would

affect, or be affected by, a decision in this proceeding: *Celltrion, Inc. v. Regeneron Pharms., Inc.*, No. IPR2024-00260 (P.T.A.B.), *Apotex Inc. v. Regeneron Pharmaceuticals, Inc.*, No. IPR2022-01524 (P.T.A.B.), *Samsung Bioepis Co., Ltd. v. Regeneron Pharms., Inc.*, IPR2023-00442 (P.T.A.B.), *Samsung Bioepis Co. Ltd. v. Regeneron Pharms., Inc.*, No. IPR2023-00739 (P.T.A.B.), *United States v. Regeneron Pharms., Inc.*, No. 1:20-cv-11217-FDS (D. Mass.), and *Horizon Healthcare Servs., Inc. v. Regeneron Pharms., Inc.*, No. 1:22-cv-10493-FDS (D. Mass.).

U.S. Patent Nos. 9,254,338 B2; 9,669,069 B2; 10,857,205 B2; 10,828,345 B2; 10,130,681 B2; 10,888,601 B2; 11,559,564 B2; 11,707,506 B2; and 11,730,794 B2; and U.S. Patent Application Nos. 17/072,417; 17/112,063; and 18/496,472 each claim the benefit of the '572 patent's purported priority date.

C. LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION (37 C.F.R. § 42.8(b)(3)-(4)).

Petitioner identifies its lead and backup counsel below.

Lead	Back-Up
Paul J. Molino (Reg. No. 45,350) paul@rmmslegal.com <u>Postal and Hand Delivery Address</u> Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 222-6300	William A. Rakoczy (<i>pro hac vice</i> to be filed) wrakoczy@rmmslegal.com Deanne M. Mazzochi (Reg. No. 50,158) dmazzochi@rmmslegal.com Heinz J. Salmen

Facsimile: (312) 843-6260 <i>Petitioner consents to email service at:</i> MYL_REG_IPR@rmmslegal.com	(<i>pro hac vice</i> to be filed) hsalmen@rmmslegal.com Eric R. Hunt (<i>pro hac vice</i> to be filed) ehunt@rmmslegal.com Neil B. McLaughlin (Reg. No. 70,810) nmclaughlin@rmmslegal.com Lauren M. Lesko (<i>pro hac vice</i> to be filed) llesko@rmmslegal.com L. Scott Beall (Reg. No. 52,601) sbeall@rmmslegal.com Thomas H. Ehrich (Reg. No. 67,122) tehrich@rmmslegal.com Steven J. Birkos (Reg. No. 65,300) sbirkos@rmmslegal.com Jake R. Ritthamel (<i>pro hac vice</i> to be filed) jritthamel@rmmslegal.com <u>Postal and Hand Delivery Address</u> Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 527-2157 Facsimile: (312) 843-6260
---	--

Please direct all correspondence to lead and back-up counsel at the contact information above. Petitioner also consents to service by email at: MYL_REG_IPR@rmmslegal.com.

Dated: January 18, 2024

Respectfully Submitted,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

/Paul J. Molino/

Paul J. Molino

Registration No. 45,350

6 West Hubbard Street

Chicago, IL 60654

Telephone: (312) 222-6300

Facsimile: (312) 843-6260

paul@rmmslegal.com

Counsel for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a true and correct copy of the foregoing Petitioner's Amended Mandatory Notices was served on January 18, 2024, via electronic mail, to the following counsel of record for Patent Owner:

Adam R. Brausa (Reg. No. 60,287)
Rebecca Weires (Reg. No. 77,895)
Duralyn J. Durie (*pro hac vice* to be filed)
Morrison & Foerster LLP
425 Market Street
San Francisco, CA 94105
Tel: 415.268,6053
Tel: 415.268.6028
Tel: 415.268.6055
abrausa@mofo.com
rweires@mofo.com
ddurie@mofo.com

Kira A. Davis (*pro hac vice* to be filed)
Morrison & Foerster LLP
707 Wilshire Blvd., Suite 6000
Los Angeles, CA 90017
Tel: 213.892,5654
kiradavis@mofo.com

Dated: January 18, 2024

Respectfully Submitted,
RAKOCZY MOLINO MAZZOCHI SIWIK LLP
/Paul J. Molino/
